Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 5, pp. 643-654
Closed Access | Times Cited: 318

Showing 1-25 of 318 citing articles:

Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 254-267
Open Access | Times Cited: 661
Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 477
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke, Piotr Rutkowski, Paola Queirolo, et al.
The Lancet (2022) Vol. 399, Iss. 10336, pp. 1718-1729
Closed Access | Times Cited: 401
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Alexander C. Huang, Roberta Zappasodi
Nature Immunology (2022) Vol. 23, Iss. 5, pp. 660-670
Open Access | Times Cited: 389
Cutaneous melanoma
Georgina V. Long, Susan M. Swetter, Alexander M. Menzies, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 485-502
Closed Access | Times Cited: 323
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 286
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, et al.
The Lancet (2024) Vol. 403, Iss. 10427, pp. 632-644
Closed Access | Times Cited: 267
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 228
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
Georgina V. Long, Jason J. Luke, Muhammad A. Khattak, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 11, pp. 1378-1388
Closed Access | Times Cited: 126
Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview
Silvie H. M. Janssen, Winette T.A. van der Graaf, Daniël J. van der Meer, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4847-4847
Open Access | Times Cited: 114
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
NEJM Evidence (2022) Vol. 1, Iss. 11
Closed Access | Times Cited: 105
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalà, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 17, pp. 3352-3361
Open Access | Times Cited: 103
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M. Kirkwood, Michele Del Vecchio, Jeffrey S. Weber, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2835-2843
Open Access | Times Cited: 99
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luís de la Cruz-Merino, Teresa M. Petrella, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 75-85
Closed Access | Times Cited: 86
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Elisabeth Livingstone, Lisa Zimmer, Jessica C. Hassel, et al.
The Lancet (2022) Vol. 400, Iss. 10358, pp. 1117-1129
Closed Access | Times Cited: 85
The Treatment of Advanced Melanoma: Therapeutic Update
Alessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6388-6388
Open Access | Times Cited: 83
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
Egesta Lopci, Rodney J. Hicks, Antonia Dimitrakopoulou-Strauß, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 7, pp. 2323-2341
Open Access | Times Cited: 79
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 65
Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
Andrew A. Guirguis, Yaara Ofir-Rosenfeld, Kathy Knezevic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 10, pp. 2228-2247
Closed Access | Times Cited: 54
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Georgina V. Long, Alexander M. Menzies, Richard A. Scolyer
Journal of Clinical Oncology (2023) Vol. 41, Iss. 17, pp. 3236-3248
Closed Access | Times Cited: 43
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 21
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 644-653
Open Access | Times Cited: 73
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
Mattia Garutti, Matteo Lambertini, Fabio Puglisi
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100276-100276
Open Access | Times Cited: 63
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
Anne Zaremba, Alexander M.M. Eggermont, Caroline Robert, et al.
European Journal of Cancer (2021) Vol. 155, pp. 268-280
Closed Access | Times Cited: 61
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 59
Page 1 - Next Page

Scroll to top